• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

News

Prior immune checkpoint inhibitor (ICI) therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry

29 de November de 2023
Int J Infect Dis. 2023 Nov 27:S1201-9712(23)00782-8. doi: 10.1016/j.ijid.2023.11.021.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2023-11-29 11:00:002023-11-29 11:00:00Prior immune checkpoint inhibitor (ICI) therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry

Ovarian cancer relies on the PDGFRβ-fibronectin axis for tumorsphere formation and metastatic spread

27 de November de 2023
Mol Oncol. 2023 Nov 27. doi: 10.1002/1878-0261.13556. Online…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-11-27 11:00:002023-11-27 11:00:00Ovarian cancer relies on the PDGFRβ-fibronectin axis for tumorsphere formation and metastatic spread

Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality

21 de November de 2023
Cancer Res. 2023 Nov 21:OF1-OF15. doi: 10.1158/0008-5472.CAN-22-2948.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2023-11-21 11:00:002023-11-21 11:00:00Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality

Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study

8 de November de 2023
Eur Urol Oncol. 2023 Nov 6:S2588-9311(23)00224-9. doi: 10.1016/j.euo.2023.10.008.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2023-11-08 11:00:002023-11-08 11:00:00Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study

Detection of the Uveal Melanoma-Associated Mutation GNAQ Q209P from Liquid Biopsy Using CRISPR/Cas12a Technology

3 de November de 2023
Anal Chem. 2023 Nov 14;95(45):16692-16700. doi: 10.1021/acs.analchem.3c03460.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2023-11-03 10:00:002023-11-03 10:00:00Detection of the Uveal Melanoma-Associated Mutation GNAQ Q209P from Liquid Biopsy Using CRISPR/Cas12a Technology

Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages

26 de October de 2023
Cell Rep. 2023 Oct 25;42(11):113382. doi: 10.1016/j.celrep.2023.113382.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-10-26 10:00:002023-10-26 10:00:00Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages

Elucidating Compound Mechanism of Action and Polypharmacology with a Large-scale Perturbational Profile Compendium

24 de October de 2023
bioRxiv. 2023 Oct 10:2023.10.08.561457. doi: 10.1101/2023.10.08.561457.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-10-24 10:00:002023-10-24 10:00:00Elucidating Compound Mechanism of Action and Polypharmacology with a Large-scale Perturbational Profile Compendium

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

23 de October de 2023
N Engl J Med. 2023 Oct 21. doi: 10.1056/NEJMoa2304753. Online…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2023-10-23 10:00:002023-10-23 10:00:00Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages

17 de October de 2023
Cell Rep. 2023 Oct 31;42(10):113256. doi: 10.1016/j.celrep.2023.113256.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-10-17 10:00:002023-10-17 10:00:00Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages

Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party

13 de October de 2023
Front Immunol. 2023 Sep 27;14:1252811. doi: 10.3389/fimmu.2023.1252811.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-10-13 10:00:002023-10-13 10:00:00Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party

A machine learning and live-cell imaging tool kit uncovers small molecules induced phospholipidosis

5 de October de 2023
Cell Chem Biol. 2023 Sep 27:S2451-9456(23)00322-7. doi: 10.1016/j.chembiol.2023.09.003.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-10-05 10:00:002023-10-05 10:00:00A machine learning and live-cell imaging tool kit uncovers small molecules induced phospholipidosis

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

20 de September de 2023
Nat Commun. 2023 Sep 20;14(1):5825. doi: 10.1038/s41467-023-41562-6.ABSTRACTTumor…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-09-20 10:00:002023-09-20 10:00:00Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Page 22 of 87«‹2021222324›»

Filter by categories

  • Alemany’s & Piulats’s lab (133)
  • Antolin's lab (36)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sin categoría (5)
  • Sureda's & Farre's Lab (312)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}